The IL-2/TCR fusion protein ALT-801, which targets the P53(aa264-272)/HLA-A*0201 complex (Additional file 3: Table S3, row 6), and the fusion protein Hu14.8-IL2 which is comprised of one molecule of anti-GD2 humanized mAb fused to two IL-2 molecules (Additional file 3: Table S3, row 7), have been combined with the administration of PB-NK cells to stimulate NK cell function against p53- or GD2-expressing tumor cells. This evidence concerns the gene IL2 and neoplasm.